Trials / Unknown
UnknownNCT04822961
Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment
A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 285 (estimated)
- Sponsor
- Impact Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Senaparib in metastatic castration-resistant prostate cancer (mCRPC) patients with homologous recombination repair (HRR) gene alterations after docetaxel treatment
Detailed description
This is a randomized, double-blinded, placebo-controlled, multicenter, Phase II study in mCRPC patients with HRR gene alterations after docetaxel therapy to evaluate the anti-tumor activity and safety of Senaparib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Senaparib-matched placebo capsules |
| DRUG | Senaparib | 20 mg capsules |
Timeline
- Start date
- 2021-12-31
- Primary completion
- 2024-05-01
- Completion
- 2024-08-01
- First posted
- 2021-03-30
- Last updated
- 2021-12-16
Locations
6 sites across 3 countries: United States, Australia, China
Source: ClinicalTrials.gov record NCT04822961. Inclusion in this directory is not an endorsement.